BRAF and melanoma: The corollary of these studies is that repressing B-RAF (or RAS) in melanoma cells triggers an alternative-signaling program, involving a switch, which allows the tumor to continue to rely on MAPK for maintenance of the malignant phenotype and drug resistance.